Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

In Vitro Activity of Combinations of Zinc Chelators with Amphotericin B and Posaconazole against Six Mucorales Species

Florencia Leonardelli, Daiana Macedo, Catiana Dudiuk, Laura Theill, Matias S. Cabeza, Soledad Gamarra, Guillermo Garcia-Effron
Florencia Leonardelli
aLaboratorio de Micología y Diagnóstico Molecular–Cátedra de Parasitología y Micología–Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina
bConsejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), CCT, Santa Fe, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daiana Macedo
aLaboratorio de Micología y Diagnóstico Molecular–Cátedra de Parasitología y Micología–Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina
bConsejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), CCT, Santa Fe, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catiana Dudiuk
aLaboratorio de Micología y Diagnóstico Molecular–Cátedra de Parasitología y Micología–Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina
bConsejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), CCT, Santa Fe, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Theill
aLaboratorio de Micología y Diagnóstico Molecular–Cátedra de Parasitología y Micología–Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matias S. Cabeza
aLaboratorio de Micología y Diagnóstico Molecular–Cátedra de Parasitología y Micología–Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina
bConsejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), CCT, Santa Fe, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soledad Gamarra
aLaboratorio de Micología y Diagnóstico Molecular–Cátedra de Parasitología y Micología–Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillermo Garcia-Effron
aLaboratorio de Micología y Diagnóstico Molecular–Cátedra de Parasitología y Micología–Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina
bConsejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), CCT, Santa Fe, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Guillermo Garcia-Effron
DOI: 10.1128/AAC.00266-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Mucormycosis is an emerging disease with high mortality rates. Few antifungal drugs are active against Mucorales. Considering the low efficacy of monotherapy, combination-therapy strategies have been described. It is known that fungi are susceptible to zinc deprivation, so we tested the in vitro effect of the zinc chelators clioquinol, phenanthroline, and N,N,N′,N′-tetrakis(2-pyridylmethyl)ethane-1,2-diamine combined with amphotericin B or posaconazole against 25 strains of Mucorales. Clioquinol-posaconazole was the most active combination, although results were strain dependent.

INTRODUCTION

Mucormycosis is a rapidly progressing fungal disease associated with high mortality (1). Few antifungal drugs are active against Mucorales, and fewer are being used as monotherapy to treat these mycoses. Mucormycosis treatment is currently limited to amphotericin B (AMB) (especially in its lipid formulations) and isavuconazole, whereas posaconazole (POS) is being used as salvage and deescalation therapy (1–3). Because the efficacy of monotherapy is suboptimal, combination therapy strategies have been described, not only between antifungal drugs but also in combination with other nonantifungal agents (2, 4, 5).

It is long known that zinc (Zn) starvation inhibits microbial growth in tissues (6). Zn deficiency induces stress in fungal cells and hampers fungal development by restricting the activity of Zn-binding proteins, which are mainly transcription factors involved in many biological processes (6, 7). Published data about Zn homeostasis in fungi have inferred that compounds that interfere with this metabolic process would inhibit fungal growth. Thus, the antifungal activity of some Zn chelators has been tested against Aspergillus fumigatus strains to evaluate their clinical application, with promising results (8, 9).

The aim of this study was to evaluate the in vitro effect of the Zn chelators 5-chloro-7-iodo-quinolin-8-ol (clioquinol [CLIO]), 1,10-phenanthroline (PHEN), and N,N,N′,N′-tetrakis(2-pyridylmethyl)ethane-1,2-diamine (TPEN) in combination with AMB and POS against clinical Mucorales strains.

Twenty-five isolates were tested, including 18 Rhizopus microsporus, 2 Rhizopus oryzae, 2 Syncephalastrum racemosum, 1 Mucor circinelloides, 1 Lichtheimia corymbifera, and 1 Cunninghamella bertholletiae. Candida parapsilosis ATCC 22019 was used as the antifungal susceptibility testing quality control strain. Mucorales isolates were identified by internal transcribed spacer sequencing (10, 11). To choose the range of drug concentrations to be tested in the combination studies, MICs of the individual Zn chelators were first determined according to CLSI M38 guidlines (12). Interactions between antifungals and Zn chelators were studied by calculating the fractional inhibitory concentration index (FICI) (13) using the same CLSI guidelines modified for a broth microdilution checkerboard procedure. The FICI data were interpreted as synergism (FICI, ≤0.5), antagonism (FICI, >4), or no interaction (FICI, >0.5 to 4) (13). All drugs were purchased from Sigma as standard powders, dissolved in dimethyl sulfoxide, and stored at −70°C.

Each isolate was tested at least three times on different days. Sporangiospore suspensions were counted in a hemocytometer chamber and then diluted into RPMI to reach a concentration of 2 × 104 sporangiospores/ml (equivalent to 0.16 OD530 [optical density at 530 nm]). The concentration ranges tested in checkerboard plates were 0.06 to 4 μg/ml for AMB, 0.12 to 8 μg/ml for POS, and 0.03 to 16 μg/ml for the Zn chelators. Microplates were incubated at 35°C, and MICs were determined visually as the lowest drug concentration (tested alone or in combination) that had no visible growth (100% inhibition). The incubation time was extended to 48 h in the combination experiment to confirm the 100% inhibition. MIC and FICI values are expressed as the geometric means (GMs) and arithmetic means, respectively, of the results obtained for the triplicates. Off-scale MIC values were converted to the next concentration (e.g., 32 for >16 μg/ml) to obtain the GMs.

A wide range of MIC values were obtained when drugs were tested alone (AMB, 0.25 to 4 μg/ml; POS, 0.50 to 4.00 μg/ml; TPEN, 0.25 to >16 μg/ml; PHEN, 2 to 8 μg/ml; and CLIO, 0.5 to >16 μg/ml) (Table 1). For AMB and POS, similar GMs were obtained (1.12 and 1.21 μg/ml, respectively). TPEN was the most active Zn chelator (MIC GM, 0.47 μg/ml), followed by PHEN (MIC GM, 3.68 μg/ml) and CLIO (MIC GM, 8 μg/ml). The studied polyene showed lower MIC values than for POS for all the species except R. microsporus (AMB versus POS GMs, 1.36 versus 1.08 μg/ml) and C. bertholletiae (4.00 μg/ml for both agents). Regarding the activity of Zn chelators, TPEN showed low MIC values for most of the strains. In contrast, MIC values for PHEN were elevated for all tested strains, whereas CLIO acted in a strain-dependent manner, with low MICs only for S. racemosum and L. corymbifera isolates. C. bertholletiae was the only isolate totally resistant to all of the Zn chelators.

View this table:
  • View inline
  • View popup
TABLE 1

Antifungal susceptibility testing results for strains used in study

Arithmetic means of FICI results and their interpretation are described in Table 2. AMB exhibited no interaction with the Zn chelators against most of the isolates (22 out of 25 strains). Synergism was only observed when the polyene was combined with CLIO against M. circinelloides and 2 R. microsporus isolates. However, it was remarkable that borderline FICI values were obtained against the R. oryzae strains with AMB+CLIO (FICI, 0.51 and 0.56), even when their AMB MICs were not similar (2 and 0.25 μg/ml) and both strains had CLIO MIC values of >16 μg/ml. The same was observed for 2 R. microsporus strains (LMDM-164 and LMDM-1127), with borderline FICI values and high CLIO MICs.

View this table:
  • View inline
  • View popup
TABLE 2

Fractional inhibitory concentration index results for all isolates and drugs in study

When POS was combined with CLIO, PHEN, and TPEN, both synergism and antagonism were seen: FICI values of ≤0.5 were observed for 6 (all R. microsporus), 3 (all R. microsporus), and 2 (1 R. oryzae and 1 C. bertholletiae) strains, respectively. On the other hand, antagonism was observed for R. microsporus isolates when tested against POS+CLIO (3 strains) and POS+PHEN (1 strain). Again, borderline FICI values resulted for POS+Zn chelator combinations against 5 R. microsporus strains and 1 S. racemosum strain.

Overall, the results obtained with AMB and Zn chelator combinations were discouraging, because no combination showed clear synergistic behavior. On the other hand, POS+CLIO showed promising results, especially against R. microsporus. However, the POS+Zn chelator combinations acted in a strain-dependent manner, as described earlier for AMB and POS (14). However, a Zn-chelator susceptibility pattern could potentially be established if a larger collection of strains was studied.

It is known that metal-chelating agents are able to inhibit biological processes that are essential in every cellular system. Zn-chelator concentration-related toxicity has been described and should be taken into consideration (15). It is thus clear that a Zn-depletion-based strategy for mucormycosis therapy would be plausible only if undesired effects of ion sequestration could be avoided with the development of fungal-specific ion chelators. This concept should be added to the drug development pipeline.

ACKNOWLEDGMENTS

This study was supported by Science, Technology and Productive Innovation Ministry (MinCyT-Argentina) grant PICT2013/1571 to S.G. and G.G.-E.

F.L. and D.M. have fellowships from CONICET (Argentina). C.D. and M.S.C. have postdoctoral fellowships from CONICET.

FOOTNOTES

    • Received 4 February 2019.
    • Returned for modification 1 March 2019.
    • Accepted 10 March 2019.
    • Accepted manuscript posted online 18 March 2019.
  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Sipsas NV,
    2. Gamaletsou MN,
    3. Anastasopoulou A,
    4. Kontoyiannis DP
    . 2018. Therapy of mucormycosis. J Fungi (Basel) 4:E90. doi:10.3390/jof4030090.
    OpenUrlCrossRef
  2. 2.↵
    1. Dannaoui E
    . 2017. Antifungal resistance in Mucorales. Int J Antimicrob Agents 50:617–621. doi:10.1016/j.ijantimicag.2017.08.010.
    OpenUrlCrossRef
  3. 3.↵
    1. McCarthy MW,
    2. Walsh TJ
    . 2016. Emerging diagnostic and therapeutic options for treating mucormycosis. Expert Opin Orphan Drugs 4:1253–1261. doi:10.1080/21678707.2016.1252672.
    OpenUrlCrossRef
  4. 4.↵
    1. Spellberg B,
    2. Ibrahim A,
    3. Roilides E,
    4. Lewis RE,
    5. Lortholary O,
    6. Petrikkos G,
    7. Kontoyiannis DP,
    8. Walsh TJ
    . 2012. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis 54:S73–S78. doi:10.1093/cid/cir885.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. McCarthy MW,
    2. Petraitis V,
    3. Walsh TJ
    . 2017. Combination therapy for the treatment of pulmonary mold infections. Expert Rev Respir Med 11:481–489. doi:10.1080/17476348.2017.1325322.
    OpenUrlCrossRef
  6. 6.↵
    1. Staats CC,
    2. Kmetzsch L,
    3. Schrank A,
    4. Vainstein MH
    . 2013. Fungal zinc metabolism and its connections to virulence. Front Cell Infect Microbiol 3:65. doi:10.3389/fcimb.2013.00065.
    OpenUrlCrossRef
  7. 7.↵
    1. Eide DJ
    . 2011. The oxidative stress of zinc deficiency. Metallomics 3:1124–1129. doi:10.1039/c1mt00064k.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Vicentefranqueira R,
    2. Amich J,
    3. Laskaris P,
    4. Ibrahim-Granet O,
    5. Latgé JP,
    6. Toledo H,
    7. Leal F,
    8. Calera JA
    . 2015. Targeting zinc homeostasis to combat Aspergillus fumigatus infections. Front Microbiol 6:160. doi:10.3389/fmicb.2015.00160.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Laskaris P,
    2. Atrouni A,
    3. Calera JA,
    4. d'Enfert C,
    5. Munier-Lehmann H,
    6. Cavaillon JM,
    7. Latgé JP,
    8. Ibrahim-Granet O
    . 2016. Administration of zinc chelators improves survival of mice infected with Aspergillus fumigatus both in monotherapy and in combination with caspofungin. Antimicrob Agents Chemother 60:5631–5639. doi:10.1128/AAC.00324-16.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Walther G,
    2. Pawłowska J,
    3. Alastruey-Izquierdo A,
    4. Wrzosek M,
    5. Rodriguez-Tudela JL,
    6. Dolatabadi S,
    7. Chakrabarti A,
    8. de Hoog GS
    . 2013. DNA barcoding in Mucorales: an inventory of biodiversity. Persoonia 30:11–47. doi:10.3767/003158513X665070.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Machouart M,
    2. Larché J,
    3. Burton K,
    4. Collomb J,
    5. Maurer P,
    6. Cintrat A,
    7. Biava MF,
    8. Greciano S,
    9. Kuijpers AF,
    10. Contet-Audonneau N,
    11. de Hoog GS,
    12. Gérard A,
    13. Fortier B
    . 2006. Genetic identification of the main opportunistic Mucorales by PCR-restriction fragment length polymorphism. J Clin Microbiol 44:805–810. doi:10.1128/JCM.44.3.805-810.2006.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Clinical and Laboratory Standards Institute. 2017. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi—3rd ed. CLSI standard M38. Clinical and Laboratory Standards Institute, Wayne, PA.
  13. 13.↵
    1. Odds FC
    . 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1. doi:10.1093/jac/dkg301.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Cornely OA,
    2. Arikan-Akdagli S,
    3. Dannaoui E,
    4. Groll AH,
    5. Lagrou K,
    6. Chakrabarti A,
    7. Lanternier F,
    8. Pagano L,
    9. Skiada A,
    10. Akova M,
    11. Arendrup MC,
    12. Boekhout T,
    13. Chowdhary A,
    14. Cuenca-Estrella M,
    15. Freiberger T,
    16. Guinea J,
    17. Guarro J,
    18. de Hoog S,
    19. Hope W,
    20. Johnson E,
    21. Kathuria S,
    22. Lackner M,
    23. Lass-Flörl C,
    24. Lortholary O,
    25. Meis JF,
    26. Meletiadis J,
    27. Muñoz P,
    28. Richardson M,
    29. Roilides E,
    30. Tortorano AM,
    31. Ullmann AJ,
    32. van Diepeningen A,
    33. Verweij P,
    34. Petrikkos G
    , European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group, European Confederation of Medical Mycology. 2014. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 3:5–26. doi:10.1111/1469-0691.12371.
    OpenUrlCrossRef
  15. 15.↵
    1. Santos AL,
    2. Sodre CL,
    3. Valle RS,
    4. Silva BA,
    5. Abi-Chacra EA,
    6. Silva LV,
    7. Souza-Goncalves AL,
    8. Sangenito LS,
    9. Goncalves DS,
    10. Souza LO,
    11. Palmeira VF,
    12. d'Avila-Levy CM,
    13. Kneipp LF,
    14. Kellett A,
    15. McCann M,
    16. Branquinha MH
    . 2012. Antimicrobial action of chelating agents: repercussions on the microorganism development, virulence and pathogenesis. Curr Med Chem 19:2715–2737. doi:10.2174/092986712800609788.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Activity of Combinations of Zinc Chelators with Amphotericin B and Posaconazole against Six Mucorales Species
Florencia Leonardelli, Daiana Macedo, Catiana Dudiuk, Laura Theill, Matias S. Cabeza, Soledad Gamarra, Guillermo Garcia-Effron
Antimicrobial Agents and Chemotherapy Apr 2019, 63 (5) e00266-19; DOI: 10.1128/AAC.00266-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Activity of Combinations of Zinc Chelators with Amphotericin B and Posaconazole against Six Mucorales Species
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Activity of Combinations of Zinc Chelators with Amphotericin B and Posaconazole against Six Mucorales Species
Florencia Leonardelli, Daiana Macedo, Catiana Dudiuk, Laura Theill, Matias S. Cabeza, Soledad Gamarra, Guillermo Garcia-Effron
Antimicrobial Agents and Chemotherapy Apr 2019, 63 (5) e00266-19; DOI: 10.1128/AAC.00266-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Mucorales
zinc chelators
antifungal susceptibility testing
posaconazole

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596